International Journal of Particle Therapy, an esteemed publication from the INT JOURNAL PARTICLE THERAPY, stands at the forefront of innovative research in the realms of particle therapy, radiology, and atomic physics. Established as an Open Access journal since 2015, it provides a platform for scholarly articles that drive the advancement of knowledge and practice in cancer treatment and radiation therapy. With an impact factor reflective of its rising stature, this journal has been categorized in the Q2 quartile for both Atomic and Molecular Physics and Radiology, Nuclear Medicine and Imaging as of 2023, illustrating its significant role in contributing to these vital fields. Researchers, professionals, and students alike will find the journal indispensable for accessing pioneering studies that explore the efficacy and application of particle therapy, ensuring that the latest advancements reach a broad audience. With a robust focus on bridging theoretical insights and clinical practices, the International Journal of Particle Therapy remains committed to enhancing patient outcomes and fostering collaboration among scientists worldwide.

The Japanese Journal of Radiology, published by SPRINGER, serves as a premier platform for disseminating cutting-edge research and clinical advancements in the fields of radiology, nuclear medicine, and imaging. With an ISSN of 1867-1071 and E-ISSN 1867-108X, this journal has established itself as a vital resource for practitioners, researchers, and students alike. Renowned for its high-quality peer-reviewed articles, it currently enjoys a respectable impact factor within the Q2 category of Scopus rankings, placing it in the 69th percentile among 333 journals in its field. The journal has seen consistent convergence of research from 2009 to 2024, further underscoring its commitment to advancing the understanding of radiological practices. Importantly, the journal offers Open Access options to facilitate widespread dissemination of knowledge, ensuring that vital research reaches its audience without barriers. Addressed in Japan, the Japanese Journal of Radiology plays a critical role in enhancing the global discourse on medical imaging, making it an essential resource for anyone engaged in this dynamic field.

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.

STRAHLENTHERAPIE UND ONKOLOGIE is an esteemed journal published by Springer Heidelberg, focusing on critical advancements and research in the fields of Oncology and Radiology. Established in 1986, this journal has carved its niche within the scientific community, ranking in the Q1 category for Radiology, Nuclear Medicine and Imaging, and Q2 for Oncology as of 2023. With an ISSN of 0179-7158 and E-ISSN 1439-099X, it serves as an essential resource for researchers, professionals, and students dedicated to the complexities of cancer treatment and radiation therapy. While the journal operates under a subscription model, its broad international readership values its rigorous peer-review process and comprehensive coverage of pivotal studies. STRAHLENTHERAPIE UND ONKOLOGIE continues to enhance its impact in the domains of oncology and radiology, as evidenced by its commendable Scopus rankings, including a 76th percentile in Radiology and a 65th percentile in Oncology. Its commitment to disseminating innovative research solidifies its role as a cornerstone in the ongoing quest to improve patient care and therapeutic techniques.

Medical Dosimetry is a distinguished journal published by Elsevier Science Inc, dedicated to the advancing field of medical dosimetry and its applications within oncology, radiology, and nuclear medicine. With its ISSN 0958-3947 and E-ISSN 1873-4022, this journal serves as a crucial resource for researchers and professionals aiming to enhance their understanding of radiation treatment planning and dosage calculations. Encompassing a comprehensive range of topics from clinical dosimetry to technology assessment, Medical Dosimetry has been disseminating significant findings since its establishment in 1988, contributing to the continuous development of best practices in patient care and safety. The journal currently holds a Q3 ranking in various categories, reflecting its pivotal role in the research community, while not currently offering open access, it remains an essential reference for scholars advancing the techniques utilized in medical imaging and treatment. By fostering a platform for high-quality research, it aims to bridge the gap between theoretical studies and clinical applications, making it a vital addition to any medical library.

Physics & Imaging in Radiation Oncology is a premier journal dedicated to advancing the interdisciplinary field of radiation oncology through innovative research and imaging technologies. Published by Elsevier, this open-access journal has made its mark since its inception in 2017, ensuring that groundbreaking findings are accessible to a broad audience. With a strong focus on the integration of physics, imaging techniques, and oncology, the journal occupies esteemed positions in the academic landscape, ranking in the top quartile for Radiation and Radiology, Nuclear Medicine and Imaging as of 2023. The journal serves as a platform for researchers, professionals, and students to share insights and foster collaboration, ultimately improving patient outcomes through enhanced imaging and treatment modalities. Based in Ireland and operating from Radarweg 29, 1043 NX Amsterdam, Netherlands, the journal aims to bridge the gap between theoretical physics and practical applications in clinical settings.

Radiological Physics and Technology, published by SPRINGER JAPAN KK, is a prominent journal that serves as a crucial resource in the multidisciplinary fields of medicine and radiation sciences. With an ISSN of 1865-0333 and an E-ISSN of 1865-0341, the journal has been converging impactful research from 2008 to 2024. It holds a commendable position in academic rankings, currently classified in Q2 in Physical Therapy, Sports Therapy and Rehabilitation and Radiation, along with Q3 for Medicine (miscellaneous) and Radiology, Nuclear Medicine and Imaging. The journal is well-regarded in the academic community, reflected in its Scopus rankings that place it in the upper tiers of its respective categories. Although it currently does not offer Open Access, Radiological Physics and Technology remains a pivotal publication for researchers, academics, and practitioners seeking to advance knowledge and foster innovation in radiological science. Its commitment to disseminating high-quality research ensures its continued relevance and importance within these fields.

Radiotherapy and Oncology is a leading peer-reviewed journal published by Elsevier Ireland Ltd, focusing on the vital fields of hematology, oncology, and radiology. With an impressive impact factor and ranking in the top quartiles (Q1) of its categories as of 2023, it is recognized for disseminating high-quality research that contributes significantly to advancements in cancer treatment and patient care. The journal, which has been in circulation since 1983, aims to provide a platform for original research articles, reviews, and clinical studies that explore the latest innovations in radiotherapeutic technologies and oncology practices. This journal is essential for researchers, healthcare professionals, and students who are dedicated to improving cancer therapies and outcomes. Although it does not offer open access, the wealth of information contained within its pages supports continued education and development in these crucial medical fields.

Radiation Oncology is a premier scholarly journal published by BMC, dedicated to advancing the field of oncology through innovative research and comprehensive reviews since its inception in 2005. With its Open Access model, the journal ensures that the latest findings in radiotherapy and cancer treatment are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and healthcare professionals. The journal has garnered an impressive reputation with prestigious rankings, achieving Q1 status in Radiology, Nuclear Medicine and Imaging and Q2 in Oncology as of 2023, reflecting its significant impact on the scientific community. In the Scopus rankings, it stands proud at Rank #61 in Radiology, Nuclear Medicine and Imaging, placing it in the top 81st percentile, and Rank #112 in Oncology at the 72nd percentile. With a converged publication plan extending through 2024, Radiation Oncology remains a vital resource for those dedicated to enhancing cancer treatment methodologies and outcomes.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.